Hippocampal dysfunction in Parkinson's disease: = Hippokampale Dysfunktion bei der Parkinson-Erkrankung
Gespeichert in:
| Beteilige Person: | |
|---|---|
| Format: | Hochschulschrift/Dissertation Buch |
| Sprache: | Englisch |
| Veröffentlicht: |
Erlangen ; Nürnberg
[2019]
|
| Schlagwörter: | |
| Links: | http://d-nb.info/1182462529/04 http://bvbr.bib-bvb.de:8991/F?func=service&doc_library=BVB01&local_base=BVB01&doc_number=030936464&sequence=000001&line_number=0001&func_code=DB_RECORDS&service_type=MEDIA |
| Umfang: | IV, 95 Seiten Illustrationen, Diagramme 21 cm |
Internformat
MARC
| LEADER | 00000nam a2200000 c 4500 | ||
|---|---|---|---|
| 001 | BV045552516 | ||
| 003 | DE-604 | ||
| 005 | 20190411 | ||
| 007 | t| | ||
| 008 | 190410s2019 gw a||| m||| 00||| eng d | ||
| 016 | 7 | |a 1182462529 |2 DE-101 | |
| 020 | |c Broschur | ||
| 035 | |a (OCoLC)1104916159 | ||
| 035 | |a (DE-599)DNB1182462529 | ||
| 040 | |a DE-604 |b ger |e rda | ||
| 041 | 0 | |a eng | |
| 044 | |a gw |c XA-DE | ||
| 049 | |a DE-29T |a DE-29 |a DE-355 | ||
| 084 | |a 610 |2 sdnb | ||
| 100 | 1 | |a Salvi, Rachele |e Verfasser |4 aut | |
| 245 | 1 | 0 | |a Hippocampal dysfunction in Parkinson's disease |b = Hippokampale Dysfunktion bei der Parkinson-Erkrankung |c vorgelegt von Rachele Salvi |
| 246 | 1 | 3 | |a Hippokampale Dysfunktion bei der Parkinson-Erkrankung |
| 246 | 1 | 1 | |a Hippokampale Dysfunktion bei der Parkinson-Erkrankung |
| 264 | 1 | |a Erlangen ; Nürnberg |c [2019] | |
| 300 | |a IV, 95 Seiten |b Illustrationen, Diagramme |c 21 cm | ||
| 336 | |b txt |2 rdacontent | ||
| 337 | |b n |2 rdamedia | ||
| 338 | |b nc |2 rdacarrier | ||
| 502 | |b Dissertation |c Friedrich-Alexander-Universität Erlangen-Nürnberg |d 2019 | ||
| 650 | 0 | 7 | |a Parkinson-Krankheit |0 (DE-588)4044683-9 |2 gnd |9 rswk-swf |
| 650 | 0 | 7 | |a Dopaminantagonist |0 (DE-588)4299915-7 |2 gnd |9 rswk-swf |
| 650 | 0 | 7 | |a Neurogenese |0 (DE-588)4331352-8 |2 gnd |9 rswk-swf |
| 650 | 0 | 7 | |a Hippocampus |0 (DE-588)4642127-0 |2 gnd |9 rswk-swf |
| 655 | 7 | |0 (DE-588)4113937-9 |a Hochschulschrift |2 gnd-content | |
| 689 | 0 | 0 | |a Parkinson-Krankheit |0 (DE-588)4044683-9 |D s |
| 689 | 0 | 1 | |a Neurogenese |0 (DE-588)4331352-8 |D s |
| 689 | 0 | 2 | |a Hippocampus |0 (DE-588)4642127-0 |D s |
| 689 | 0 | 3 | |a Dopaminantagonist |0 (DE-588)4299915-7 |D s |
| 689 | 0 | |5 DE-604 | |
| 856 | 4 | 2 | |m B:DE-101 |q application/pdf |u http://d-nb.info/1182462529/04 |3 Inhaltsverzeichnis |
| 856 | 4 | 2 | |m DNB Datenaustausch |q application/pdf |u http://bvbr.bib-bvb.de:8991/F?func=service&doc_library=BVB01&local_base=BVB01&doc_number=030936464&sequence=000001&line_number=0001&func_code=DB_RECORDS&service_type=MEDIA |3 Inhaltsverzeichnis |
| 943 | 1 | |a oai:aleph.bib-bvb.de:BVB01-030936464 | |
Datensatz im Suchindex
| _version_ | 1819316821143060480 |
|---|---|
| adam_text | TABLE
OF
CONTENTS
LIST
OF
FIGURES
..........................................................................................................................................
-1
-
LIST
OF
TABLES
............................................................................................................................................
-
2
-
DECLARATION
..............................................................................................................................................
-
3
-
SUMMARY
.................................................................................................................................................
-
4
-
ZUSAMMENFASSUNG
..................................................................................................................................
-
6
-
1
INTRODUCTION
..................................................................................................................................
-
9
-
1.1
PARKINSON
*S
DISEASE
(PD):
A-SYNUCLEINOPATHY
............................................................................
-
9
-
1.1.1
EPIDEMIOLOGY
AND
CLINIC
.....................................................................................................
-9-
1.1.2
ETIOLOGY
AND
PATHOGENESIS
.................................................................................................
-
9
-
1.1.3
THERAPY
OF
PD...................................................................................................................
-11-
1.1.3.1
L-DOPA
....................................................................................................................
-H
-
1.1.3.2
DA
AGONISTS:
PRAMIPEXOLE
(PPX)
AND
ROPINEROLE
(ROP)
.......................................
-12
-
1.1.4
IN
VIVO
MODELS
OF
PD:
A-SYN
TRANSGENIC
MOUSE
MODELS
..................................................
-13
-
1.2
HIPPOCAMPUS
............................................................................................................................
-14
-
1.2.1
STRUCTURE
AND
FUNCTION
.....................................................................................................
-
14
-
1.2.2
OVERALL
NEUROANATOMICAL
ORGANIZATION
OF
DO:
LAYERS
AND
MAJOR
AFFERENT
PROJECTIONS
....
-
15
-
1.2.3
HIPPOCAMPAL
NEUROGENESIS
.............................................................................................
-17-
1.2.4
NEUROGENESIS
IN
A
*
NON-NEUROGENIC
*
REGION:
STRIATUM
(STR)
..........................................
-
18
-
1.2.5
DAERGIC
PROJECTIONS
TO
THE
HIP
AND
THE
STR
.................................................................
-
19
-
1.2.6
HIPPOCAMPAL
ATROPHY
IN
PD
...........................................................................................
-
20
-
1.3
NEUROINFLAMMATION
IN
PD
.......................................................................................................
-
20
-
2
HYPOTHESES
OF
THE
THESIS
.............................................................................................................
-
22
-
3
MATERIALS
AND
METHODS
..............................................................................................................
-
23
-
3.1
MATERIALS
.........................................................................................................................................
-23-
3.1.1
CHEMICALS
.........................................................................................................................
-23-
3.1.2
KITS
AND
MASTER
MIXES
...........................................
..........................................................
-
23
-
3.1.3
DNA
AND
PROTEIN
STANDARDS
...............................................................................................
-
23
-
3.1.4
BUFFERS
AND
SOLUTIONS
........................................................................................................
-23
-
3.1.5
REAGENTS
AND
DISPOSABLES
.................................................................................................
-25
-
I
3.1.6
ANTIBODIES
.........................................................................................................................
-26
-
3.1.6.1
PRIMARY
ANTIBODIES
...................................................................................................
-
26
-
3.1.6.2
SECONDARY
ANTIBODIES
...............................................................................................
-
27
-
3.1.7
TECHNICAL
DEVICES
..............................................................................................................
-
27
-
3.1.8
SOFTWARE
.............................................................................................................................
-28-
3.2
METHODS
......................................................................................................................................
-28-
3.2.1
ANIMALS
AND
EXPERIMENTAL
DESIGN
.....................................................................................
-
28
-
3.2.1.1
C57BL/
6
MICE
...........................................................
-29-
3.2.1.2
CAM_A-SYN
TO
MICE
...............................................................................................
-
30
-
3.2.2
HISTOLOGICAL
METHODS
.........................................................................................................
-
30
-
3.2.2.1
IMMUNOHISTOCHEMISTRY
..............................................................................................
-
30
-
3.2.2.2
IMMUNOFLUORESCENCE
.................................................................................................
-31-
3.2.2.3
NISSL
STAINING
.............................................................................................................
-
31
-
3.2.2.4
COUNTING
PROCEDURES
FOR
IMMUNOHISTOCHEMISTRY
AND
NISSL
STAINING
......................
-
32
-
3.2.2.5
COUNTING
PROCEDURES
FOR
IMMUNOFLUORESCENCE
........................................................
-
34
-
3.2.2.6
ANALYSIS
OF
DENDRITES
.................................................................................................
-
35
-
3.2.2.7
QUANTIFICATION
OF
THE
AREAS
CORRESPONDING
TO
MICROGLIA
AND
ASTROCYTES
..................
-
36
-
3.2.3
BIOCHEMICAL
METHODS
........................................................................................................
-
37
-
3.2.3.1
SEQUENTIAL
PROTEIN
EXTRACTION
AND
DETERMINATION
OF
PROTEIN
CONCENTRATION
.............
-
37
-
3.2.3.2
WESTERN
BLOT
..............................................................................................................
-
37
-
3.2.4
STATISTICS
.............................................................................................................................
-38-
4
RESULTS
.........................................................................................................................................
-
39
-
4.1
EFFECTS
OF
DA
AGONISTS
ON
HIPPOCAMPAL
NEUROGENESIS
AND
STRIATAL
GENERATION
OF
NEUROBLASTS
IN
ADULT
C57BL/
6
MICE
.........................................................................................
-
39
-
4.1.1
PPX,
BUT
NOT
ROP
ENHANCES
PROLIFERATION
OF
NPCS
IN
THE
HIPPOCAMPAL
DG
..................
-
39
-
4.1.2
PPX
DOUBLES
ADULT
HIPPOCAMPAL
NEUROGENESIS
.................................................................
-
39
-
4.1.3
PPX
INDUCES
THE
GENERATION
OF
OCX-POSITIVE
NEUROBLASTS
IN
THE
DSTR
........................
-
41
-
4.2
ROLE
OF
HUMAN
WILD-TYPE
A-SYN
IN
THE
ALTERATION
OF
HIPPOCAMPAL
MORPHOLOGY,
BIOCHEMISTRY
AND
INFLAMMATORY
RESPONSE
IN
A
MOUSE
MODEL
OF
PD
........................................
-
44
-
4.2.1
EXPRESSION
PATTERN
OF
HUMAN
WILD-TYPE
A-SYN
IN
THE
HIP
OF
CAM
A-SYN
MICE
.............
-
45
-
4.2.1
A-SYN
OVEREXPRESSION
INDUCES
MORPHOLOGICAL
CHANGES
IN
THE
DG
OF
CAM
A-SYN
MICE
...................................................................................................................................
-
45
-
4.2.1.1
THE
DG
VOLUME,
BUT
NOT
THE
ENTIRE
DORSAL
HIP
VOLUME,
IS
REDUCED
IN
YOUNG
AND
AGED
TG
MICE
DUE
TO
A
MASSIVE
LOSS
OF
GCS
...................................................
-
45
-
4.2.2
A-SYN
EXERTS
DIFFERENTIAL
EFFECTS
ON
DISTINCT
STAGES
OF
ADULT
HIPPOCAMPAL
NEUROGENESIS
AND
PROMOTES
PRE-SYNAPTIC
ALTERATION
.........................................................
-
48
-
II
4.2.2.1
PROLIFERATION
OF
NEWLY
GENERATED
CELLS
IS
ALTERED
IN
THE
SGZ
OF
YOUNG
CAMA-
SYN
MICE
..................................................................................................................
-
48
-
4.2.2.2
ADULT
HIPPOCAMPAL
NEUROGENESIS
(DCX-POSITIVE
CELLS)
IS
NOT
REDUCED
IN
YOUNG
AND
AGED
CAM_A-SYN
MICE
.........................................................................
-
48
-
4.2.23
THE
LEVEL
OF
SYNAPSIN-
1
IS
SIGNIFICANTLY
REDUCED
IN
YOUNG,
BUT
NOT
IN
AGED
CAM_A-SYN
MICE
....................................................................................................
-
50
-
4.2.3
A-SYN
OVEREXPRESSION
AFFECTS
LOCATION
AND
DENDRITIC
OUTGROWTH
OF
NEUROBLASTS
IN
THE
DG
OF
CAM_A-SYN
MICE
...................................................................................................
-
53
-
4.23.1
DCX-POSITIVE
CELLS
ARE
ECTOPICALLY
LOCATED
IN
THE
GCL
AND
ML
OF
YOUNG
CAM_A-SYN
MICE
....................................................................................................
-
53
-
4.23.2
ECTOPIC
DCX-POSITIVE
CELLS
ARE
NOT
PROLIFERATING
(MCM2-POSITIVE),
BUT
POST
MITOTIC
CELLS
(CALRETININ-POSITIVE)
..........................................................................
-
55
-
4.2.33
DENDRITIC
OUTGROWTH
OF
DCX-POSITIVE
CELLS
IS
INCREASED
IN
YOUNG
CAM_A-SYN
MICE
.......................................................................................................................
-
56
-
4.2.4
INVOLVEMENT
OF
A-SYN
IN
GLIAL
ALTERATION
...........................................................................
-
57
-
4.2.4.1
ASTROGLIOSIS
AND
MICROGLIOSIS
ARE
ENHANCED
AND
LONG-LASTING
IN
THE
DG
OF
YOUNG
CAM
A-SYN
MICE
....................................................................................................
-
57
-
5
DISCUSSION
...................................................................................................................................
-
60
-
5.1
THE
DIFFERENTIAL
EFFECT
OF
THE
ADMINISTRATION
OF
TWO
DA
AGONISTS,
PPX
AND
ROP
ON
MURINE
NEUROGENESIS
.............................................................................................................................
-
60
-
5.1.1
THE
ROLE
OF
PPX
IN
THE
MODULATION
OF
NPCS
PROLIFERATION
AND
GENERATION
OF
NEW
NEURONS
IN
THE
DG
............................................................................................................
-
60
-
5.1.2
THE
INVOLVEMENT
OF
PPX
IN
THE
FORMATION
OF
STRIATAL
NEUROBLASTS
...................................
-
63
-
5.2
THE
ROLE
OF
A-SYN
IN
MORPHOLOGICAL,
NEUROGENIC,
AND
INFLAMMATORY
CHANGES
OBSERVED
IN
A
MURINE
MODEL
OF
PD
(CAM
A-SYN
MODEL)
............................................................................
-
65
-
5.2.1
DISTRIBUTION
OF
A-SYN
IN
REGIONS
OF
THE
HIP
CONTAINING
AXONAL
PROJECTIONS
AND
INTERNEURONS
......................................................................................................................
-
66
-
5.2.2
THE
IMPACT
OF
A-SYN
OVEREXPRESSION
ON
THE
VOLUME
OF
THE
DG
AND
ON
THE
NUMBER
OF
GCS
...................................................................................................................................
-67-
5.23
THE
EFFECT
OF
A-SYN
ON
NPCS
PROLIFERATION
AND
GENERATION
OF
NEUROBLASTS
WITHIN
THE
GCL
AS
WELL
AS
ON
SYNAPTIC
CHANGES
IN
THE
HIP
..............................................................
-
69
-
5.2.4
THE
ROLE
OF
A-SYN
IN
THE
DEFECTIVE
MIGRATION
OF
DCX-POSITIVE
CELLS
IN
THE
DG
AND
ENHANCED
DENDRITIC
OUTGROWTH
..........................................................................................
-
73
-
5.2.5
INFLUENCE
OF
A-SYN
OVEREXPRESSION
ON
THE
NEUROINFLAMMATORY
RESPONSE
IN
THE
DG
......
-
76
-
6
CONCLUSIONS
-
79
-
III
7
BIBLIOGRAPHY
....................................................................................................................................
-
81
-
8
ABBREVIATIONS
..................................................................................................................................
-
92
-
9
ACKNOWLEDGMENT
.............................................................................................................................
-
95
-
IV
|
| any_adam_object | 1 |
| author | Salvi, Rachele |
| author_facet | Salvi, Rachele |
| author_role | aut |
| author_sort | Salvi, Rachele |
| author_variant | r s rs |
| building | Verbundindex |
| bvnumber | BV045552516 |
| ctrlnum | (OCoLC)1104916159 (DE-599)DNB1182462529 |
| discipline | Medizin |
| format | Thesis Book |
| fullrecord | <?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>02021nam a2200469 c 4500</leader><controlfield tag="001">BV045552516</controlfield><controlfield tag="003">DE-604</controlfield><controlfield tag="005">20190411 </controlfield><controlfield tag="007">t|</controlfield><controlfield tag="008">190410s2019 gw a||| m||| 00||| eng d</controlfield><datafield tag="016" ind1="7" ind2=" "><subfield code="a">1182462529</subfield><subfield code="2">DE-101</subfield></datafield><datafield tag="020" ind1=" " ind2=" "><subfield code="c">Broschur</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(OCoLC)1104916159</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)DNB1182462529</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-604</subfield><subfield code="b">ger</subfield><subfield code="e">rda</subfield></datafield><datafield tag="041" ind1="0" ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="044" ind1=" " ind2=" "><subfield code="a">gw</subfield><subfield code="c">XA-DE</subfield></datafield><datafield tag="049" ind1=" " ind2=" "><subfield code="a">DE-29T</subfield><subfield code="a">DE-29</subfield><subfield code="a">DE-355</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">610</subfield><subfield code="2">sdnb</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Salvi, Rachele</subfield><subfield code="e">Verfasser</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Hippocampal dysfunction in Parkinson's disease</subfield><subfield code="b">= Hippokampale Dysfunktion bei der Parkinson-Erkrankung</subfield><subfield code="c">vorgelegt von Rachele Salvi</subfield></datafield><datafield tag="246" ind1="1" ind2="3"><subfield code="a">Hippokampale Dysfunktion bei der Parkinson-Erkrankung</subfield></datafield><datafield tag="246" ind1="1" ind2="1"><subfield code="a">Hippokampale Dysfunktion bei der Parkinson-Erkrankung</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="a">Erlangen ; Nürnberg</subfield><subfield code="c">[2019]</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">IV, 95 Seiten</subfield><subfield code="b">Illustrationen, Diagramme</subfield><subfield code="c">21 cm</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="b">n</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="b">nc</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="502" ind1=" " ind2=" "><subfield code="b">Dissertation</subfield><subfield code="c">Friedrich-Alexander-Universität Erlangen-Nürnberg</subfield><subfield code="d">2019</subfield></datafield><datafield tag="650" ind1="0" ind2="7"><subfield code="a">Parkinson-Krankheit</subfield><subfield code="0">(DE-588)4044683-9</subfield><subfield code="2">gnd</subfield><subfield code="9">rswk-swf</subfield></datafield><datafield tag="650" ind1="0" ind2="7"><subfield code="a">Dopaminantagonist</subfield><subfield code="0">(DE-588)4299915-7</subfield><subfield code="2">gnd</subfield><subfield code="9">rswk-swf</subfield></datafield><datafield tag="650" ind1="0" ind2="7"><subfield code="a">Neurogenese</subfield><subfield code="0">(DE-588)4331352-8</subfield><subfield code="2">gnd</subfield><subfield code="9">rswk-swf</subfield></datafield><datafield tag="650" ind1="0" ind2="7"><subfield code="a">Hippocampus</subfield><subfield code="0">(DE-588)4642127-0</subfield><subfield code="2">gnd</subfield><subfield code="9">rswk-swf</subfield></datafield><datafield tag="655" ind1=" " ind2="7"><subfield code="0">(DE-588)4113937-9</subfield><subfield code="a">Hochschulschrift</subfield><subfield code="2">gnd-content</subfield></datafield><datafield tag="689" ind1="0" ind2="0"><subfield code="a">Parkinson-Krankheit</subfield><subfield code="0">(DE-588)4044683-9</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="0" ind2="1"><subfield code="a">Neurogenese</subfield><subfield code="0">(DE-588)4331352-8</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="0" ind2="2"><subfield code="a">Hippocampus</subfield><subfield code="0">(DE-588)4642127-0</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="0" ind2="3"><subfield code="a">Dopaminantagonist</subfield><subfield code="0">(DE-588)4299915-7</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="0" ind2=" "><subfield code="5">DE-604</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="m">B:DE-101</subfield><subfield code="q">application/pdf</subfield><subfield code="u">http://d-nb.info/1182462529/04</subfield><subfield code="3">Inhaltsverzeichnis</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="m">DNB Datenaustausch</subfield><subfield code="q">application/pdf</subfield><subfield code="u">http://bvbr.bib-bvb.de:8991/F?func=service&doc_library=BVB01&local_base=BVB01&doc_number=030936464&sequence=000001&line_number=0001&func_code=DB_RECORDS&service_type=MEDIA</subfield><subfield code="3">Inhaltsverzeichnis</subfield></datafield><datafield tag="943" ind1="1" ind2=" "><subfield code="a">oai:aleph.bib-bvb.de:BVB01-030936464</subfield></datafield></record></collection> |
| genre | (DE-588)4113937-9 Hochschulschrift gnd-content |
| genre_facet | Hochschulschrift |
| id | DE-604.BV045552516 |
| illustrated | Illustrated |
| indexdate | 2024-12-20T18:30:09Z |
| institution | BVB |
| language | English |
| oai_aleph_id | oai:aleph.bib-bvb.de:BVB01-030936464 |
| oclc_num | 1104916159 |
| open_access_boolean | |
| owner | DE-29T DE-29 DE-355 DE-BY-UBR |
| owner_facet | DE-29T DE-29 DE-355 DE-BY-UBR |
| physical | IV, 95 Seiten Illustrationen, Diagramme 21 cm |
| publishDate | 2019 |
| publishDateSearch | 2019 |
| publishDateSort | 2019 |
| record_format | marc |
| spellingShingle | Salvi, Rachele Hippocampal dysfunction in Parkinson's disease = Hippokampale Dysfunktion bei der Parkinson-Erkrankung Parkinson-Krankheit (DE-588)4044683-9 gnd Dopaminantagonist (DE-588)4299915-7 gnd Neurogenese (DE-588)4331352-8 gnd Hippocampus (DE-588)4642127-0 gnd |
| subject_GND | (DE-588)4044683-9 (DE-588)4299915-7 (DE-588)4331352-8 (DE-588)4642127-0 (DE-588)4113937-9 |
| title | Hippocampal dysfunction in Parkinson's disease = Hippokampale Dysfunktion bei der Parkinson-Erkrankung |
| title_alt | Hippokampale Dysfunktion bei der Parkinson-Erkrankung |
| title_auth | Hippocampal dysfunction in Parkinson's disease = Hippokampale Dysfunktion bei der Parkinson-Erkrankung |
| title_exact_search | Hippocampal dysfunction in Parkinson's disease = Hippokampale Dysfunktion bei der Parkinson-Erkrankung |
| title_full | Hippocampal dysfunction in Parkinson's disease = Hippokampale Dysfunktion bei der Parkinson-Erkrankung vorgelegt von Rachele Salvi |
| title_fullStr | Hippocampal dysfunction in Parkinson's disease = Hippokampale Dysfunktion bei der Parkinson-Erkrankung vorgelegt von Rachele Salvi |
| title_full_unstemmed | Hippocampal dysfunction in Parkinson's disease = Hippokampale Dysfunktion bei der Parkinson-Erkrankung vorgelegt von Rachele Salvi |
| title_short | Hippocampal dysfunction in Parkinson's disease |
| title_sort | hippocampal dysfunction in parkinson s disease hippokampale dysfunktion bei der parkinson erkrankung |
| title_sub | = Hippokampale Dysfunktion bei der Parkinson-Erkrankung |
| topic | Parkinson-Krankheit (DE-588)4044683-9 gnd Dopaminantagonist (DE-588)4299915-7 gnd Neurogenese (DE-588)4331352-8 gnd Hippocampus (DE-588)4642127-0 gnd |
| topic_facet | Parkinson-Krankheit Dopaminantagonist Neurogenese Hippocampus Hochschulschrift |
| url | http://d-nb.info/1182462529/04 http://bvbr.bib-bvb.de:8991/F?func=service&doc_library=BVB01&local_base=BVB01&doc_number=030936464&sequence=000001&line_number=0001&func_code=DB_RECORDS&service_type=MEDIA |
| work_keys_str_mv | AT salvirachele hippocampaldysfunctioninparkinsonsdiseasehippokampaledysfunktionbeiderparkinsonerkrankung AT salvirachele hippokampaledysfunktionbeiderparkinsonerkrankung |